摘要
目的:观察吉西他滨治疗高龄晚期非小细胞肺癌的疗效,并与同期单纯支持治疗的患者比较,以探讨高龄晚期非小细胞肺癌的治疗方案。方法:吉西他滨组21例,采用吉西他滨单药化疗,剂量为1250mg/m2,静脉滴注,第1、8天用药,每21天为1周期,共4周期。对照组23例不用任何化疗,单纯支持对症治疗。结果:吉西他滨组总有效率为28.6%,其中PR6例,SD12例,PD3例。对照组无CR和PR者。吉西他滨组中位缓解期6.3个月。吉西他滨组和对照组中位肿瘤进展时间分别为5.8和2.6个月,中位生存时间分别为12.8和4.6个月(P<0.01);1年生存率分别为46.6%和9.2%(P<0.01)。吉西他滨组KPS、体重增加和临床症状改善情况均显著高于对照组(P<0.01)。毒副反应方面吉西他滨组12例(57.1%)出现Ⅰ、Ⅱ级血小板减少,7例(33.3%)出现Ⅰ、Ⅱ级白细胞下降,未见Ⅲ、Ⅳ级毒性反应。少数患者血红蛋白下降Ⅰ度,恶心呕吐Ⅰ/Ⅱ度。结论:吉西他滨单药治疗高龄晚期非小细胞肺癌是安全有效的。
Purpose:To observe the effective of gemcitabine in elderly patients(pts) with advanced non-small-cell lung cancer(NSCLC), compared to supportive care alone. Methods:Gemcitabine group (n=21), received gecitabine (1 250) mg/m^(2), on days 1 and 8,using 21-day schedule, total 4 cycles. Control group (n=23) , using supportive care alone. Results:The overall response rate of gemcitabine group was 28.6%, 6 had partial response(PR), 12 had stable disease(SD),3 had progression disease(PD).No patient had complete responses (CR) and PR in control group. The median duration of response was 6.3 months in gemcitabine group, the median survival was 12.8 and 4.6 months respectively (P<(0.01)); 1-year survival 46.6% and 9.2% respectively (P<0.01). KPS, weight and clinical symptoms improved markedly in gemcitabine group (P<0.01). Gemcitabine group, grade Ⅰ/Ⅱ thrombocytopenia and neutropenia occurred in 12 ((57.1%)) and 7 (33.3%)of patients respectively, no grade Ⅲ/Ⅳ toxicity. Conclusions:Gemcitabine is a safe and effective in the gemcitabine of elderly advanced NSCLC patients.
出处
《中国癌症杂志》
CAS
CSCD
2005年第2期171-172,共2页
China Oncology
关键词
非小细胞肺癌
吉西他滨
高龄患者
non-small-cell lung cancer
Gemcitabine
elderly patients
